The authors conclude that adrenal function is commonly suppressed immediately following conventional short-term therapy with glucocorticoids. Adrenal function typically returns to normal in almost all patients within two weeks, but suppression can persist in up to 25 percent of patients and for several weeks or months in a small proportion of patients. Patients are vulnerable to impaired stress response and other adverse effects when their adrenal response is suppressed. Unfortunately, it is impossible to identify ahead of time which patients will be affected, as adrenal suppression cannot be predicted based on dosage, or type or duration of therapy. Therefore, the authors urge vigilant follow-up of patients after glucocorticoid therapy.
If you have questions about any of the clinical pathways or about the process of creating a clinical pathway please contact us .
©2017 by Children's Hospital of Philadelphia, all rights reserved.
The clinical pathways are based upon publicly available medical evidence and/or a consensus of medical practitioners at The Children’s Hospital of Philadelphia (“CHOP”) and are current at the time of publication. These clinical pathways are intended to be a guide for practitioners and may need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, and/or the availability of various resources at the health care institution where the patient is located.
Accordingly, these clinical pathways are not intended to constitute medical advice or treatment, or to create a doctor-patient relationship between/among The Children’s Hospital of Philadelphia (“CHOP”), its physicians and the individual patients in question. CHOP does not represent or warrant that the clinical pathways are in every respect accurate or complete, or that one or more of them apply to a particular patient or medical condition. CHOP is not responsible for any errors or omissions in the clinical pathways, or for any outcomes a patient might experience where a clinician consulted one or more such pathways in connection with providing care for that patient.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: 18 Years and older (Adult, Senior) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population The study will be open to all women over the age of 18 scheduled to begin standard of care chemotherapy for a gynecologic malignancy, either every 3 weeks (carboplatin and taxol) or weekly (cisplatin). The study is restricted by gender due to the population of interest being women with gynecologic malignancies. Criteria Inclusion Criteria: